Pertuzumab Perjeta®
The SHIKARI® Pertuzumab portfolio provides two quantitative free-drug formats—ligand-binding and mAb-based specific detection—plus one qualitative anti-pertuzumab antibody assay.
Why Pertuzumab is relevant to biological-drug monitoring research
Pertuzumab has clinically important target biology, indication-specific dosing and measurable systemic exposure, making drug concentration and immunogenicity relevant research variables. Scientific source ↗ · EMA source ↗
Molecular Target & Structure
Pertuzumab is a humanised IgG1 monoclonal antibody that binds the HER2 extracellular dimerisation domain (subdomain II), inhibiting HER2 heterodimerisation with other HER-family receptors. Source ↗
Approved Indications
EMA-authorised uses include HER2-positive metastatic breast cancer and defined neoadjuvant/adjuvant treatment of HER2-positive early breast cancer in combination regimens. EMA source ↗
Steady-State and Persistence
A clean universal Cmin/Cmax target is not provided in the current label; regulator PK data instead establish time to steady state and persistence under the approved 840 mg loading / 420 mg Q3W regimen:
Regulatory exposure values are regimen- and population-specific and are not therapeutic targets. Values vary with dose, timing, formulation and study population. This page is for RUO product information and does not provide clinical guidance.
Three verified Pertuzumab research assays
Ligand-binding ELISA for quantitative analysis of free pertuzumab in human serum or plasma.
Monoclonal anti-idiotypic, mAb-based ELISA for specific quantitative determination of free pertuzumab in human serum or plasma.
Qualitative ELISA for positive or negative assessment of anti-pertuzumab antibodies in human serum or plasma according to assay-specific cut-off interpretation.
Verified Specifications at a Glance
| Kit | REF | Mode | Analyte | Sample | Volume | Time | Analytical output | Tests | Shelf life | Storage | Shipping |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SHIKARI® Q-PER | PER-FD-PER | Quantitative | Free pertuzumab | Human serum / plasma | 5 µL | 70 min | LOD 30 ng/mL; LOQ 30 ng/mL | 96 | 1 year | 2–8°C | 10–30°C |
| SHIKARI® QS-PER | PER-SPEC-PER | Quantitative | Free pertuzumab | Human serum / plasma | 5 µL | 70 min | LOD 10 ng/mL; LOQ 10 ng/mL | 96 | 1 year | 2–8°C | 10–30°C |
| SHIKARI® S-ATPER | PER-QLS-PER | Qualitative | Anti-pertuzumab antibodies | Human serum / plasma | 20 µL | 140 min | Positive / negative | 96 | 1 year | 2–8°C | 10–30°C |
Analytical specifications are summarised from the current controlled IFUs and exact official product records. Standard curves are official illustrative product images and must not be used for sample quantification. Follow the link on each assay card for the corresponding product record on matriksbiotek.com.
Match the assay to the research question
Pertuzumab Literature and Product-Use Records
Planning a Pertuzumab research study?
Matrix Biotek can help identify the appropriate Pertuzumab assay and prepare regional quotation and delivery information.